866-997-4948(US-Canada Toll Free)

Yondelis (Ovarian Cancer) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Ovarian Cancer

No. of Pages : 31 Pages

 

GlobalDatas pharmaceuticals report, Yondelis (Ovarian Cancer) - Analysis and Forecasts to 2020 provides Yondelis sales forecasts for EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2009-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

 

Scope

 

  • Therapy area profile including patient population for EU5
  • Analysis and review of Yondelis including sales data 
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Yondelis including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2009-2020 for Yondelis in EU

 

Reasons to buy

 

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Contents

 

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3


2 Introduction 4
2.1 Ovarian Cancer 4
2.2 Ovarian Cancer Market 4
2.3 Epidemiology 4
2.4 Etiology 6
2.4.1 Age 6
2.4.2 Inherited Gene Mutations 6
2.4.3 A Previous Cancer Diagnosis 6
2.4.4 Early Menstruation or Late menopause 7
2.4.5 Family History of Ovarian Cancer 7
2.5 GlobalData Report Guidance 7


3 Ovarian Cancer: Market Characterization 8
3.1 Ovarian Cancer Market 8
3.2 Ovarian Cancer Market Forecasts and CAGR 8
3.3 Drivers for Ovarian Cancer Market 9
3.3.1 High Incidence 9
3.3.2 High Mortality Rate 10
3.3.3 Increased Use of Chemotherapy in Ovarian Cancer 11
3.3.4 Emergence of Targeted Drugs 11
3.3.5 Recurrence of Tumor 11
3.3.6 Low Initial Diagnosis Rate 11


4 Tumor-Node-Metastases (TNM) Classification of Ovarian Cancer 12


5 Yondelis (trabectedin) 15
5.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Yondelis 16
5.5 Factors Affecting Sales of Yondelis 16
5.5.1 Yondelis/Doxil Combination 16
5.5.2 Efficacy 16
5.5.3 Adverse Events 16
5.5.4 Orphan Drug Status 17
5.5.5 Licensing in Japan 17
5.5.6 Rejection by NICE in the UK 17
5.6 Drug Evaluation 17
5.6.1 Drug Risk Benefit Score 17
5.6.2 Intensity of Competition 18
5.7 Sales Estimates 18
5.7.1 Target Patient Pool of Yondelis 18
5.7.2 Dosing 19
5.7.3 Market Penetration 19
5.7.4 Annual Cost of Therapy 20
5.7.5 Sales Projections of Yondelis 20


6 Ovarian Cancer Market: Appendix 27
6.1 Market Definitions 27
6.2 List of Abberiviations 27
6.3 Research Methodology 27
6.3.1 Coverage 27
6.3.2 Secondary Research 28
6.3.3 Forecasting 28
6.3.4 Number of Patients Approved to take the Drug 28
6.3.5 Net Penetration of Drug 28
6.3.6 Net Annual Dosing 30
6.3.7 Annual Cost of Therapy 30
6.3.8 Primary Research 30
6.3.9 Expert Panels 30
6.4 Contact Us 30
6.5 Disclaimer 30
6.6 Sources 31

List of Table


Table 1: Ovarian Cancer, Incidences and Mortality, 20082030 6
Table 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Table 3: Detailed TNM Classification 13
Table 4: Phase III Clinical Study Results for Yondelis in Ovarian Cancer 16
Table 5: Approval History of Yondelis 16
Table 6: Drug Risk Benefit Score of Yondelis 17
Table 7: Annual Cost of Therapy of Yondelis, 2011 20
Table 8: Yondelis, Ovarian Cancer, EU-5, Sales Estimates ($m), 20092020 21
Table 9: Yondelis, Ovarian Cancer, The UK, Sales Estimates ($m), 20092020 21
Table 10: Yondelis, Ovarian Cancer, France, Sales Estimates ($m), 20092020 22
Table 11: Yondelis, Ovarian Cancer, Germany, Sales Estimates ($m), 20092020 23
Table 12: Yondelis, Ovarian Cancer, Italy, Sales Estimates ($m), 20092020 24
Table 13: Yondelis, Ovarian Cancer, Spain, Sales Estimates ($m), 20092020 25

List of Chart


Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 5
Figure 2: Ovarian Cancer, Global, Market Size Forecasts ($m), 20092020 8
Figure 3: Ovarian Cancer, Worldwide, Incidence (in million), 2008-2030 9
Figure 4: Oncology, Worldwide, Incidence (in million), 2008-2030 10
Figure 5: Ovarian Cancer, Worldwide, Mortality (in million), 2008-2030 10
Figure 6: Broad Classification of Ovarian Cancer 12
Figure 7: Classification of Ovarian Cancer 14
Figure 8: Drug Model Diagram of Yondelis 19
Figure 9: Yondelis, Ovarian Cancer, EU-5, Sales Estimates ($m), 20092020 20
Figure 11: Yondelis, Ovarian Cancer, The UK, Sales Estimates ($m), 20092020 21
Figure 12: Yondelis, Ovarian Cancer, France, Sales Estimates ($m), 20092020 22
Figure 13: Yondelis, Ovarian Cancer, Germany, Sales Estimates ($m), 20092020 23
Figure 14: Yondelis, Ovarian Cancer, Italy, Sales Estimates ($m), 20092020 24
Figure 15: Yondelis, Ovarian Cancer, Spain, Sales Estimates ($m), 20092020 25
Figure 16: Yondelis, Ovarian Cancer, Europe, Sales Distribution, 2019 26
Figure 17: Drug Model Diagram 29
Figure 18: Patients Approved for the Drug 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *